Amgen’s Uplizna wins European Commission approval for generalized myasthenia gravis | iPharmaCenter
Amgen has secured European Commission clearance for Uplizna (inebilizumab) as an add‑on therapy for adults with generalized myasthenia gravis (gMG) who test positive for anti‑acetylcholine receptor (AChR) or anti‑muscle‑specific tyrosine kinase (MuSK) antibodies. The decision introduces a targeted B‑cell–depleting option that can be given as two loading infusions followed by maintenance dosing twice a year, with the aim of providing sustained disease control alongside existin
GSK’s ultra‑long‑acting IL‑5 biologic Exdensur wins EU approval for severe asthma and CRSwNP | iPharmaCenter
Exdensur (depemokimab), GSK’s new ultra‑long‑acting anti‑IL‑5 biologic, has been granted marketing authorisation by the European Commission for two respiratory indications: severe asthma driven by type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP). It is the first biologic in the EU that can be used across respiratory diseases with a twice‑yearly dosing schedule, and the approval is supported by four phase III studies – SWIFT‑1, SWIFT‑2, ANCHOR‑1 and AN
The Pharma Top 10: Highest Revenue Drugs of 2025 (Official Sales Data & Analysis) | Top selling pharmaceutical drugs | iPharmaCenter
Get the definitive ranking of the top-selling pharmaceutical drugs by global revenue in 2025. See which blockbusters—from Keytruda to the GLP-1 therapies like Ozempic and Mounjaro—are leading the market and driving record sales in Oncology and Immunology.
Top 10 Pharmaceutical Companies by Revenue 2025: Best-Selling Drugs Analysis | iPharmaCenter
Top pharmaceutical companies by revenues in 2025. The revenues are captured from the official websites of pharmaceutical companies
Lilly to Acquire Novel CAR-T Innovator Orna Therapeutics for $2.4 Billion to Advance In Vivo Cell Therapy Platform
Eli Lilly has entered into a definitive agreement to acquire Orna Therapeutics, a biotechnology firm pioneering the development of immune cell therapies engineered directly within the body. The transaction is valued at up to $2.4 billion, including an upfront payment and milestone-based potential payouts. Also read: UCB presented long-term BE HEARD trial in patients with Hidradenitis Suppurativa Advancing In Vivo CAR-T and Genetic Medicine Orna Therapeutics is building a pi
EHSF 2026: UCB presented long-term BE HEARD trial in patients with Hidradenitis Suppurativa
UCB has released long-term BE HEARD trial data showing that bimekizumab (Bimzelx) delivered deep and durable improvements in hidradenitis suppurativa over three years, with results showcased at the European Hidradenitis Suppurativa Foundation (EHSF) 2026 meeting. The new analyses highlight bimekizumab’s capacity not only to clear inflammatory lesions but also to remodel disease severity categories and reduce structurally destructive draining tunnels over time. Long-term HS re